Prognostic value and clinical correlations of serum cereblon (CRBN) levels in multiple myeloma patients treated with Lenalidomide/Dexamethasone (RD)

Autor:	Niki Rougkala, Annita Ioanna Gkioka, Aspasia Koudouna, Theodoros Iliakis, Thomais Tryfou, Maria Dimou, Marie-Christine Kyrtsonis, Paraskevi Papaioannou, Ioannis Grafakos, Aikaterini Bitsani, Panayiotis Panayiotidis, Vasileios Pardalis, Panagiotis Repousis
Rok vydání:	2019
Předmět:	Oncology Cancer Research medicine.medical_specialty business.industry Cereblon Hematology medicine.disease Internal medicine medicine business Value (mathematics) Multiple myeloma Dexamethasone Lenalidomide medicine.drug
Zdroj:	Clinical Lymphoma Myeloma and Leukemia. 19:e117
ISSN:	2152-2650
DOI:	10.1016/j.clml.2019.09.194
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::1a34dfaeee80663fab8fe98de16aa388 https://doi.org/10.1016/j.clml.2019.09.194 Zobrazit plný text záznamu Full Text from ScienceDirect